Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Indapamide Articles

Optimal thiazide dose sought in Japan

3 November 2008

Cheap BP drugs could save many type 2 diabetic patients' lives

10 September 2007

Bulgarian pharma market grows 18.5%

4 June 2007

Good start for Merck KGaA generics in Italy

5 December 2001

Chiesi of Italy sets out expansion plans for rest of Europe

29 November 2001

Stroke prevention emerges from heart disease

10 January 2001

Kangyu acquires Zhejiang firm

27 September 1999

FDA plans review of guidances on development of generic drugs

14 July 1999

Chiesi Aims For Top 20 Place In Italian Market

5 August 1998

Servier Seeks German Acquisition

9 December 1996

Interim Financial Results From The USA

18 November 1996

Faulding Receive US Approval For Indapamide

24 June 1996

UK Industry Code of Practice: latest Report

4 March 1996

Disease ManagementThe Way Forward

15 May 1995

PRYOR REPORT SLAMS INDUSTRY OVER PRICES

7 February 1994

COVERSYL GAINS US APPROVAL

31 January 1994

RHONE-POULENC RORER BID FOR OTC DRUG LINK UP

10 January 1994

RHONE-POULENC: A TRANSFORMATION

16 August 1993

ARCOLA LAUNCHES FIRST GENERIC DRUG

9 August 1993

STRONG FIRST QUARTER FOR R-PR

26 April 1993

FRANCE'S SERVIER COMING OUT OF SHELL?

8 March 1993

RHONE-POULENC RORER NET INCOME UP 13.4%

2 November 1992

Showing 1-22 of 22 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS